TriAgenics has completed its $5 million series A-3 funding round, bringing the total amount of funding raised to $12.5 million.
The company's Zero3 TBA technology is designed to provide a one-minute preventive treatment for children to stop third-molar development, eliminating the need for surgical removal. Funds will support U.S. Food and Drug Administration review and research for a U.S. market launch this year.
.hpp4JFpXkV.png?crop=focalpoint&fit=crop&fp-x=0.5&fp-y=0.5&h=167&w=250&auto=format%2Ccompress&q=70)
